ANI Pharmaceuticals ANIP

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.43 (-0.70%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of ANI Pharmaceuticals (ANIP)
    ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $60.62

    • Market Cap

      $1.27 Billion

    • Price-Earnings Ratio

      -58.29

    • Total Outstanding Shares

      20.96 Million Shares

    • Total Employees

      642

    • Dividend

      No dividend

    • IPO Date

      September 13, 1999

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      210 main street west, Baudette, MN, 56623

    • Homepage

      https://www.anipharmaceuticals.com

    Historical Stock Splits

    If you bought 6 shares of ANIP before June 4, 2012, you'd have 1 share today.
    Execution DateSplit Amount
    June 4, 20121-for-6 (Reverse Split)

    Cash Flow Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Net Cash Flow From Investing Activities$-404.72 Million
    Net Cash Flow From Investing Activities, Continuing$-404.72 Million
    Net Cash Flow From Financing Activities$264.94 Million
    Net Cash Flow From Operating Activities, Continuing$64.02 Million
    Net Cash Flow From Operating Activities$64.02 Million
    Net Cash Flow, Continuing$-75.76 Million

    Income Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Income/Loss From Continuing Operations After Tax$-18.52 Million
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$1.63 Million
    Net Income/Loss$-18.52 Million
    Benefits Costs and Expenses$636.59 Million
    Basic Average Shares$19.32 Million
    Operating Expenses$613.79 Million

    Comprehensive Income

    January 1, 2024 to December 31, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Parent$-22.04 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss$-22.04 Million
    Other Comprehensive Income/Loss$-3.51 Million

    Balance Sheet

    January 1, 2024 to December 31, 2024
    MetricValue
    Assets$1.28 Billion
    Equity Attributable To Parent$403.68 Million
    Noncurrent Assets$756.01 Million
    Intangible Assets$541.83 Million
    Equity$403.68 Million
    Other Non-current Assets$157.32 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ANIP from trusted financial sources

      Related Companies

      Additional publicly traded companies similar to ANI Pharmaceuticals (ANIP)
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.